[(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] octadecanoate | 1021442-39-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] octadecanoate
• CAS: 1021442-39-6
• 化学式: C₃₈H₆₂O₇
• 分子量: 630.906
• InChiKey: DOKZEROVYMUKBB-DZXNXGCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  45
• 可旋转键数：
  19
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  在 高氯酸 作用下， 以 甲醇 为溶剂， 生成 [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] octadecanoate
  参考文献：
  名称：

  Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation

  摘要：

  The persistence of latent reservoirs of HIV-1 represents a major barrier to virus eradication in patients treated with antiretrovirals. Prostratin is a non-tumor promoting 12-deoxyphorbol monoester capable of up-regulating viral expression from latent provirus and therefore is potentially useful for HIV adjuvant therapy and similar properties might be elicited by related non-tumor promoting phorboids. We have therefore investigated a series of phorbol 13-monoesters for their capacity to reactivate HIV latency. Using a Jurkat T cell line containing latent HIV proviruses, we found that prostratin and phorbol-13-stearate effectively activate HIV-1 gene expression in these latently infected cells, with phorbol-13-stearate being at least 10-fold more potent than prostratin, and its activity rapidly decreasing with a shortening of the acyl side chain. We further demonstrated that phorbol-13-stearate and prostratin stimulate IKK-dependent phosphorylation and degradation of I kappa B alpha, leading to activation of NF-kappa B. Moreover, prostratin, phorbol-13-hexanoate and phorbol-13-stearate also activate the JNK and ERK pathways. Studies with isoform-specific PKC inhibitors suggest that the classical PKCs play a prominent role in the responses elicited by phorbol-13-stearate. Nevertheless, this compound induces a translocation pattern of the PKC isotypes alpha and delta to cellular compartments distinctly different from that elicited by prostratin and PMA. (c) 2007 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bcp.2007.12.004

文献信息

• DOSAGE REGIMEN FOR HIV VACCINE
  申请人：BIONOR IMMUNO AS

  公开号：US20180140694A1

  公开（公告）日：2018-05-24

  The present invention relates to a novel dosage regimen in the treatment of HIV infections and AIDS. In particular, the present invention relates to a specific novel use of formulations of HIV-specific protein therapeutics, such as anti-HIV-1 specific antibodies and/or HIV-specific vaccine peptides, administered in a dosing regimen together with a latent viral reservoir purging agent. The formulations may further be administered with one or more other therapeutic agents, such as in combination with at least one immunomodulatory compound and/or other reservoir purging agents, such as histone deacetylase (HDAC) inhibitors.
• [EN] DOSAGE REGIMEN FOR HIV VACCINE<br/>[FR] SCHÉMA POSOLOGIQUE POUR UN VACCIN CONTRE LE VIH
  申请人：BIONOR IMMUNO AS

  公开号：WO2016177833A1

  公开（公告）日：2016-11-10

  The present invention relates to a novel dosage regimen in the treatment of HIV infections and AIDS. In particular, the present invention relates to a specific novel use of formulations of HIV-specific protein therapeutics, such as anti-HIV-1 specific antibodies and/or HIV-specific vaccine peptides, administered in a dosing regimen together with a latent viral reservoir purging agent. The formulations may further be administered with one or more other therapeutic agents, such as in combination with at least one immunomodulatory compound and/or other reservoir purging agents, such as histone deacetylase (HDAC) inhibitors.